Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RenalytixRENXF Receivables Turnover is 1.68 as of Dec. 2025. The stock has 3 warning signs investors should review. Among 658 Healthcare Providers & Services companies, Renalytix ranks worse than 79.94% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Renalytix's Revenue for the
six
months ended in Dec. 2025 was $1.60 Mil. Renalytix's average Accounts Receivable for the
six
months ended in Dec. 2025 was $0.95 Mil.
Hence, Renalytix's Receivables Turnover for the
six
months ended in Dec. 2025 was 1.68.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Renalytix Receivables Turnover Related Terms
Renalytix Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Renalytix's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RENXF vs VEEV, BTSG, TEM: Receivables Turnover Comparison
For the Health Information Services subindustry, Renalytix's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Renalytix Receivables Turnover vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Renalytix's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Renalytix's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Renalytix (RENXF) has a Receivables Turnover of 1.68 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Renalytix and its competitors. According to the industry distribution chart, Renalytix ranks #526 out of 658 companies in the Healthcare Providers & Services industry, placing it in the top 79.9%.
Is Renalytix's Receivables Turnover too high?
Renalytix's current Receivables Turnover is 1.68. The Healthcare Providers & Services industry median Receivables Turnover is 7.78. Renalytix's value of 1.68 is 78.4% below this industry median. Based on the distribution chart, Renalytix ranks #526 out of 658 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers.
How does Renalytix's Receivables Turnover compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Renalytix ranks #526 out of 658 companies for Receivables Turnover. This places Renalytix in the lower half of its industry. The industry median Receivables Turnover is 7.78. Renalytix's value of 1.68 is 78.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Healthcare Providers & Services company?
The median Receivables Turnover among Healthcare Providers & Services companies is 7.78, based on 658 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Renalytix's current Receivables Turnover of 1.68 is 78.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Renalytix and its competitors. For the Healthcare Providers & Services industry, the median Receivables Turnover is 7.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Renalytix's current Receivables Turnover is 1.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Renalytix stock overvalued right now?
Based on GuruFocus' analysis, Renalytix (RENXF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.06, compared to a current price of $0.04 — trading 39.8% below its estimated fair value. The current Receivables Turnover is 1.68 and 78.4% below the Healthcare Providers & Services industry median of 7.78. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Renalytix (RENXF), the current Receivables Turnover is 1.68 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease. Its product, KidneyIntelX, is designed to improve kidney disease diagnosis and prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company's service, KidneyIntelX.dkd, enables the assessment of risk for early-stage chronic kidney disease progression. KidneyIntelX uses a proprietary algorithm combining blood-based biomarkers, inherited genetics, and electronic health record data to generate a patient risk score predicting rapid kidney function decline.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RENXF has been successfully added to your 
